Table 2. Median waiting times, and crude and adjusted proportions of patients treated with radiotherapy (RT) within 60 days from date of diagnosis, by various factors.
| Total cases | No. (%) of cases receiving RT | Median wait (days) | Propn. treated within 60 days (%) | Adjusteda propn. treated within 60 days (%) | |
|---|---|---|---|---|---|
| Cancer network of residence | |||||
| Ab | 12 611 | 1442 (11.4%) | 42 | 67.3 | 70.6 |
| B | 72 783 | 16775 (23.0%) | 62 | 49.1 | 46.4 |
| Cb | 28 771 | 5547 (19.3%) | 52 | 56.9 | 58.8 |
| Db | 42 015 | 10 001 (23.8%) | 63 | 48.1 | 46.8 |
| E | 58 188 | 11 707 (20.1%) | 50 | 58.1 | 54.9 |
| F | 45 889 | 9947 (21.7%) | 54 | 55.0 | 53.4 |
| G | 59 750 | 12 094 (20.2%) | 61 | 49.9 | 47.1 |
| H | 33 032 | 7327 (22.2%) | 49 | 61.3 | 61.4 |
| Ic | 54 469 | 10 809 (19.8%) | 56 | 53.7 | 53.7 |
| J | 58 050 | 13 231 (22.8%) | 54 | 56.0 | 55.0 |
| K | 60 907 | 11 003 (18.1%) | 65 | 45.7 | 43.7 |
| Lb | 14 386 | 2652 (18.4%) | 62 | 48.9 | 45.7 |
| M | 64 226 | 15 818 (24.6%) | 52 | 55.8 | 55.4 |
| Other/not known | 592 | 91 (15.4%) | 49 | 64.8 | 58.9 |
| Test for heterogeneity | χ2=1079.7 (P<0.001) | χ2=1263.6 (P<0.001) | |||
| Year of diagnosis | |||||
| 1992c | 59 518 | 12 181 (20.5%) | 45 | 63.6 | 63.6 |
| 1993 | 56 926 | 11 654 (20.5%) | 48 | 62.0 | 61.1 |
| 1994 | 59 066 | 12 855 (21.8%) | 49 | 59.8 | 58.9 |
| 1995 | 59 746 | 12 982 (21.7%) | 53 | 56.5 | 55.8 |
| 1996 | 62 526 | 13 787 (22.0%) | 55 | 55.3 | 53.9 |
| 1997 | 62 912 | 14 411 (22.9%) | 56 | 53.9 | 52.0 |
| 1998 | 61 827 | 13 717 (22.2%) | 58 | 51.7 | 48.9 |
| 1999 | 61 773 | 13 221 (21.4%) | 64 | 46.5 | 43.4 |
| 2000 | 62 241 | 12 297 (19.8%) | 70 | 43.0 | 38.9 |
| 2001 | 59 134 | 11 339 (19.2%) | 76 | 39.6 | 35.4 |
| Test for trend | χ2=2675.6 (P<0.001) | χ2=3107.9 (P<0.001) | |||
| Cancer site | |||||
| Head and neck | 17 303 | 9688 (56.0%) | 54 | 57.4 | 56.3 |
| Oesophagus | 14 437 | 3340 (23.1%) | 46 | 63.8 | 53.0 |
| Colon | 44 150 | 1222 (2.8%) | 70 | 42.5 | 36.1 |
| Rectumc | 25 707 | 5831 (22.7%) | 54 | 56.5 | 56.5 |
| Lung | 82 155 | 26 389 (32.1%) | 35 | 73.1 | 61.9 |
| Nonmelanoma skin cancer | 17 718 | 2630 (14.8%) | 48 | 63.1 | 57.2 |
| Breast | 89 164 | 34 162 (38.3%) | 71 | 38.3 | 38.9 |
| Breast in situ | 5955 | 1192 (20.0%) | 74 | 35.0 | 37.7 |
| Uterus | 17 181 | 7051 (41.0%) | 68 | 42.3 | 40.9 |
| Prostate | 55 047 | 9211 (16.7%) | 95 | 31.0 | 29.5 |
| Bladder | 31 545 | 4820 (15.3%) | 69 | 42.2 | 32.2 |
| Brain | 9872 | 3945 (40.0%) | 35 | 82.9 | 82.0 |
| Brain, benign | 6445 | 548 (8.5%) | 56 | 53.7 | 55.0 |
| Non-Hodgkin's lymphoma | 19 956 | 3072 (15.4%) | 64 | 46.7 | 42.0 |
| Other | 169 034 | 15 343 (9.1%) | 45 | 62.3 | 56.1 |
| Test for heterogeneity | χ2=11381.8 (P<0.001) | χ2=5899.7 (P<0.001) | |||
| IMD quintile | |||||
| 1c | 112 942 | 25 112 (22.2%) | 58 | 52.0 | 52.0 |
| 2 | 119 629 | 25 400 (21.2%) | 58 | 51.9 | 50.5 |
| 3 | 120 101 | 25 681 (21.4%) | 57 | 52.7 | 50.5 |
| 4 | 128 505 | 26 811 (20.9%) | 55 | 53.9 | 50.3 |
| 5 | 123 740 | 25 350 (20.5%) | 54 | 55.6 | 50.7 |
| Not known | 752 | 90 (12.0%) | 50 | 63.3 | 65.6 |
| Test for trend | χ2=85.3 (P<0.001) | χ2=4.78 (P=0.03) | |||
| Age at diagnosis | |||||
| <50c | 70 609 | 20 341 (28.8%) | 63 | 47.6 | 47.6 |
| 50–59 | 79 565 | 24 294 (30.5%) | 62 | 48.8 | 50.4 |
| 60–69 | 132 666 | 34 725 (26.2%) | 58 | 51.5 | 50.3 |
| 70–79 | 180 470 | 35 024 (19.4%) | 52 | 56.4 | 53.1 |
| 80+ | 142 359 | 14 060 (9.9%) | 43 | 65.4 | 60.6 |
| Test for trend | χ2=1258.8 (P<0.001) | χ2=349.9 (P<0.001) | |||
| Sex | |||||
| Malec | 297 123 | 57 426 (19.3%) | 50 | 58.4 | 58.4 |
| Female | 308 546 | 71 018 (23.0%) | 62 | 49.1 | 58.4 |
| Test for heterogeneity | χ2=1097.6 (P<0.001) | χ2=0.0 (P=0.95) | |||
| All cases | 605 669 | 128 444 (21.2%) | 56 | 53.2 |
a
Adjusted for all other factors, and for survival.
b
TCR covers only a part of this network.
c
Reference group.
Tests for heterogeneity and trend exclude ‘other’ and ‘not known’ categories.